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Purpose of the study
DRV/r has been evaluated in a large-scale clinical program
in a broad range of HIV-1-infected antiretroviral-naïve
and -experienced patients (pts). This analysis examines
the safety profile of DRV/r in pts in these studies adminis-
tered DRV/r 600/100 mg BID or 800/100 mg QD, as part
of combination therapy.
Methods
All available safety data at 48 weeks were analysed from
1,376 pts recruited to the DRV/r 600/100 mg BID and
800/100 mg QD arms of Phase IIb POWER 1 + 2 trials and
Phase III ARTEMIS, TITAN and DUET trials. In ARTEMIS,
treatment-naïve pts received 800/100 mg QD (n = 343) or
lopinavir/r (LPV/r) 800/200 mg (total daily dose; n =
346); all pts received tenofovir/emtricitabine. In TITAN,
treatment-experienced, LPV-naïve pts received DRV/r
600/100 mg BID (n = 298) or LPV/r 400/100 mg BID (n
= 297) + OBR. In POWER 1 + 2, highly treatment-experi-
enced pts who only received DRV/r 600/100 mg BID +
OBR (n = 131) were included. Only pts from the control
arm of DUET 1 + 2 (n = 604) receiving DRV/r 600/100 mg
+ OBR and etravirine (ETR) placebo were analysed.
Summary of results
Most common adverse events (AEs) (regardless of causal-
ity or severity) were diarrhoea and nausea. Comparing
across all trials, there was a lower incidence of overall AEs,
serious AEs, discontinuations due to AEs and lipid AEs in
naïve pts receiving DRV/r 800/100 mg QD than in treat-
ment-experienced pts using DRV/r 600/100 mg BID. The
lower incidence of grade 2–4 at least possibly treatment-
related diarrhoea with DRV/r compared to LPV/r was seen
in both ARTEMIS and TITAN (see table in Figure 1). No
apparent differences were seen with gender, race or age.
Conclusion
In conclusion, DRV/r was consistently well tolerated and
caused significantly less grade 2–4 diarrhoea than LPV/r.
In ARTEMIS, the incidence of grade 2–4 diarrhoea and
nausea with DRV/r 800/100 mg QD was half that reported
with DRV/r 600/100 mg BID in TITAN; this could be
related to population, background regimen and/or dosing
differences.
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